Unione Europea - estone - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Unione Europea - estone - EMA (European Medicines Agency)

janssen-cilag international n.v. - abirateroonatsetaat - eesnäärmevähk - endokriinset ravi - zytiga tähistab prednisoon või prednisoloon:ravi metastaatilise kastreerimine vastupidav eesnäärme vähk on täiskasvanud mehed, kes on asümptomaatilised või kergelt sümptomaatiline pärast rikke androgeeni puudust ravi kellele keemiaravi ei ole veel kliiniliselt indicatedthe ravi metastaatilise kastreerimine vastupidav eesnäärme vähk on täiskasvanud mehed, kelle haigus on edasi arenenud, või pärast docetaxel põhinevat keemiaravi raviskeemi.

Unione Europea - estone - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Estonia - estone - Ravimiamet

krka d.d. novo mesto - estsitalopraam - suus dispergeeruv tablett - 20mg 30tk; 20mg 56tk; 20mg 84tk; 20mg 60tk; 20mg 90tk; 20mg 28tk

Estonia - estone - Ravimiamet

first pharma oÜ - estsitalopraam - õhukese polümeerikattega tablett - 10mg 50tk; 10mg 20tk; 10mg 14tk; 10mg 49tk; 10mg 200tk; 10mg 500tk; 10mg 98tk

Estonia - estone - Ravimiamet

g.l. pharma gmbh - estsitalopraam - õhukese polümeerikattega tablett - 10mg 7tk; 10mg 28tk; 10mg 30tk; 10mg 14tk; 10mg 49tk; 10mg 60tk; 10mg 56tk

Estonia - estone - Ravimiamet

teva pharma b.v. - estsitalopraam - õhukese polümeerikattega tablett - 10mg 7tk; 10mg 500tk; 10mg 28tk; 10mg 56tk; 10mg 200tk; 10mg 60tk; 10mg 112tk; 10mg 20tk; 10mg 120tk; 10mg 30tk

Estonia - estone - Ravimiamet

h. lundbeck a/s - estsitalopraam - õhukese polümeerikattega tablett - 10mg 20tk; 10mg 49tk; 10mg 500tk; 10mg 200tk; 10mg 100tk; 10mg 98tk; 10mg 14tk; 10mg 56tk; 10mg 28tk; 10mg 50tk

Estonia - estone - Ravimiamet

g.l. pharma gmbh - estsitalopraam - õhukese polümeerikattega tablett - 20mg 7tk; 20mg 20tk; 20mg 56tk; 20mg 50tk; 20mg 98tk; 20mg 15tk; 20mg 500tk; 20mg 14tk; 20mg 49tk; 20mg 28tk; 20mg 100tk; 20mg 90tk; 20mg 84tk

Estonia - estone - Ravimiamet

teva b.v. - estsitalopraam - õhukese polümeerikattega tablett - 20mg 98tk; 20mg 30tk; 20mg 60tk; 20mg 100tk; 20mg 50tk; 20mg 28tk; 20mg 56tk; 20mg 14tk